Key Opinion Leaders Highlighted Iomab-B's Future in Bone Marrow Transplant; Event Video Posted
Hillard Lazarus, MD, Pioneer Transplanter and Roland Turck, MD, Radiopharmaceutical Commercialization Veteran Detailed Unmet Medical Need and Development Path for Iomab-B
NEW YORK, NY--(May 26, 2015) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, recently hosted a Key Opinion Leader (KOL) Breakfast for healthcare investors and industry professionals at the NY Palace Hotel. A complete video of this event, as well as brief highlights from the presentations are available and posted for viewing at http://www.actiniumpharma.com/investors/media-content/.
The panelists discussed the dire need for new therapies for older patients with hematologic malignancies including acute myeloid leukemia (AML), and the curative role of bone marrow transplant. Iomab-B was described as having efficacy and safety superior to that of traditional myeloablative regimens, and likely to markedly increase the number of patients eligible for transplant. An update on the upcoming Phase 3 clinical trial of Iomab-B, plus clinical positioning and positive commercial prospects were also provided, and can be viewed online.
The meeting featured bone marrow transplant and hematology specialist Hillard M. Lazarus, MD, a Professor of Medicine at Case Western Reserve University (CWRU) School of Medicine, as well as Disease Team Leader and Director of Novel Cell Therapy at University Hospitals, Case Medical Center, and Company Scientific Advisory Board Member. Also featured was radiopharmaceutical industry veteran Roland U. Turck, MD, Managing Partner at TurckBio and recently-appointed Senior Advisor to the Actinium Board of Directors. Dr. Turck has extensive, unparalleled experience in the launch and commercialization of radiopharmaceuticals.
Dr. Lazarus performed the first bone marrow transplant in Ohio in 1976, and has had a seminal impact on multiple aspects of transplantation He now heads several clinical trials at the National Center for Regenerative Medicine (CWRU). He has over 500 publications and has won a variety of lifetime achievement, distinguished alumnus, and cancer research awards, in addition to fellowships sponsored by the Leukemia Society of America and the American Cancer Society.
Dr. Turck was formerly the head of Bayer's Global Specialty Medicine business, where he helped lead the commercialization of Xofigo, the first alpha particle-emitting radioactive agent, whose launch has been the most commercially successful of any radiopharmaceutical product to date. He is an expert in biopharmaceutical specialty medicine with more than 20 years of pharmaceutical industry experience at Bayer, Berlex, and Schering, having developed and commercialized several major oncology products on a global scale, including Xofigo, Stivarga, Nexavar, and Campath.
Those interested in learning more about Iomab-B or bone marrow transplantation are encouraged to view filmed highlights, or the full-length video of the presentations, which are available in the media section of the Company's website, at http://www.actiniumpharma.com/investors/media-content/.
About Bone Marrow Transplant:
Bone marrow transplants (BMT) are most commonly used to treat leukemia and lymphoma, conditions incurred when a blood or immune cell, respectively, becomes cancerous and proliferates. Together, these diseases account for some 50,000 to 75,000 new cases annually in the United States. BMT involves first clearing a patient's body of his or her own immune cells and then transplanting bone marrow, the source of all blood- and immune-forming cells, from a tissue-matched donor. The new cells, which are free of cancer, repopulate the patient's bone marrow and eventually give rise to a functioning set of blood and immune cells, providing a lifelong cure. BMT offers the chance of a "curative" outcome (2+ year survival), and therefore can play a central role in the treatment of AML. The impact of BMT on AML continues to increase with AML being the most common and fastest growing indication for allogeneic BMT, comprising 25% to 30% of all BMT recipients. There are currently over 100,000 BMT survivors across all indications and this number is expected to increase to 250,000 by 2020 and 500,000 by 2030, with 25% of them over age 60.
Iomab-B™ is being developed to prepare patients for hematopoietic stem cell transplantation (HSCT) and will enter a single, pivotal Phase 3 clinical study in relapsed/refractory AML. Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM).
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
David Gould, MD
SVP, Finance and Corporate Development